Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

NASDAQ:SUPN - US8684591089 - Common Stock

43.94 USD
-0.49 (-1.1%)
Last: 8/26/2025, 10:23:08 AM
Fundamental Rating

7

SUPN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SUPN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. SUPN is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, SUPN could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

SUPN had positive earnings in the past year.
SUPN had a positive operating cash flow in the past year.
In the past 5 years SUPN has always been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 4.67%, SUPN belongs to the best of the industry, outperforming 87.05% of the companies in the same industry.
With an excellent Return On Equity value of 6.06%, SUPN belongs to the best of the industry, outperforming 85.49% of the companies in the same industry.
SUPN has a Return On Invested Capital of 4.10%. This is amongst the best in the industry. SUPN outperforms 81.35% of its industry peers.
SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 15.38%.
The 3 year average ROIC (2.70%) for SUPN is below the current ROIC(4.10%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.67%
ROE 6.06%
ROIC 4.1%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

SUPN's Profit Margin of 9.70% is amongst the best of the industry. SUPN outperforms 84.97% of its industry peers.
SUPN's Profit Margin has declined in the last couple of years.
SUPN has a better Operating Margin (10.98%) than 83.94% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
SUPN has a better Gross Margin (89.87%) than 94.30% of its industry peers.
SUPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.98%
PM (TTM) 9.7%
GM 89.87%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SUPN has more shares outstanding
Compared to 5 years ago, SUPN has more shares outstanding
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 6.32 indicates that SUPN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.32, SUPN belongs to the best of the industry, outperforming 80.31% of the companies in the same industry.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.32
ROIC/WACC0.41
WACC9.96%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 2.58 indicates that SUPN has no problem at all paying its short term obligations.
SUPN has a Current ratio (2.58) which is in line with its industry peers.
SUPN has a Quick Ratio of 2.43. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SUPN (2.43) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.43
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.29%, which is quite impressive.
The Earnings Per Share has been growing slightly by 3.78% on average over the past years.
The Revenue has been growing slightly by 5.54% in the past year.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)86.29%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%150%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%

3.2 Future

SUPN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.07% yearly.
SUPN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.74% yearly.
EPS Next Y-14.87%
EPS Next 2Y-6.54%
EPS Next 3Y17.02%
EPS Next 5Y22.07%
Revenue Next Year5.81%
Revenue Next 2Y11.6%
Revenue Next 3Y12.58%
Revenue Next 5Y10.74%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.48, SUPN is valued correctly.
Based on the Price/Earnings ratio, SUPN is valued cheaper than 88.08% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.03. SUPN is valued rather cheaply when compared to this.
SUPN is valuated rather expensively with a Price/Forward Earnings ratio of 19.81.
SUPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 76.17% of the companies in the same industry.
SUPN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.63.
Industry RankSector Rank
PE 13.48
Fwd PE 19.81
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

SUPN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SUPN is cheaper than 88.08% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaply inside the industry as 87.05% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.26
EV/EBITDA 10.35
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of SUPN may justify a higher PE ratio.
SUPN's earnings are expected to grow with 17.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)3.57
EPS Next 2Y-6.54%
EPS Next 3Y17.02%

More info and screens

0

5. Dividend

5.1 Amount

SUPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (8/26/2025, 10:23:08 AM)

43.94

-0.49 (-1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners108.97%
Inst Owner Change0.42%
Ins Owners4.08%
Ins Owner Change1.82%
Market Cap2.46B
Analysts80
Price Target43.86 (-0.18%)
Short Float %9.46%
Short Ratio5.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.64%
Min EPS beat(2)15.55%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)84.8%
Min EPS beat(4)15.55%
Max EPS beat(4)158.74%
EPS beat(8)6
Avg EPS beat(8)68.65%
EPS beat(12)7
Avg EPS beat(12)29.71%
EPS beat(16)9
Avg EPS beat(16)22.79%
Revenue beat(2)1
Avg Revenue beat(2)2.29%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)6.02%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.08%
Revenue beat(12)8
Avg Revenue beat(12)2.78%
Revenue beat(16)11
Avg Revenue beat(16)2.43%
PT rev (1m)10.26%
PT rev (3m)10.82%
EPS NQ rev (1m)24.74%
EPS NQ rev (3m)-30.29%
EPS NY rev (1m)24.95%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)8.4%
Revenue NQ rev (3m)7.08%
Revenue NY rev (1m)6.28%
Revenue NY rev (3m)8.52%
Valuation
Industry RankSector Rank
PE 13.48
Fwd PE 19.81
P/S 3.7
P/FCF 13.26
P/OCF 13.17
P/B 2.32
P/tB 5.29
EV/EBITDA 10.35
EPS(TTM)3.26
EY7.42%
EPS(NY)2.22
Fwd EY5.05%
FCF(TTM)3.31
FCFY7.54%
OCF(TTM)3.34
OCFY7.59%
SpS11.86
BVpS18.97
TBVpS8.3
PEG (NY)N/A
PEG (5Y)3.57
Profitability
Industry RankSector Rank
ROA 4.67%
ROE 6.06%
ROCE 6.66%
ROIC 4.1%
ROICexc 7.83%
ROICexgc N/A
OM 10.98%
PM (TTM) 9.7%
GM 89.87%
FCFM 27.94%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.48%
Cap/Sales 0.18%
Interest Coverage 250
Cash Conversion 121.69%
Profit Quality 288.18%
Current Ratio 2.58
Quick Ratio 2.43
Altman-Z 6.32
F-Score8
WACC9.96%
ROIC/WACC0.41
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)86.29%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%150%
EPS Next Y-14.87%
EPS Next 2Y-6.54%
EPS Next 3Y17.02%
EPS Next 5Y22.07%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%
Revenue Next Year5.81%
Revenue Next 2Y11.6%
Revenue Next 3Y12.58%
Revenue Next 5Y10.74%
EBIT growth 1Y56.36%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year3.46%
EBIT Next 3Y20.29%
EBIT Next 5Y21.99%
FCF growth 1Y161.05%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y160.89%
OCF growth 3Y10.6%
OCF growth 5Y3.74%